Lilly Alzheimer’s drug trial yields promising sign
by Tom Murphy, AP Business Writer
August 24, 2012 11:30 AM | 371 views | 0 0 comments | 3 3 recommendations | email to a friend | print
INDIANAPOLIS (AP) _ A treatment for Alzheimer’s disease from drugmaker Eli Lilly yielded promising signs in late-stage research, even though the drug failed to slow mental decline in two separate studies of patients with mild-to-moderate cases of the mind-robbing condition.

The Indianapolis drugmaker’s shares climbed nearly 6 percent, or $2.50, to $44.90 Friday in pre-market trading.

Alzheimer’s disease has no cure, and many patients typically live four to eight years after diagnosis, as the disease gradually erodes their memory and ability to think or perform simple tasks.

Eli Lilly and Co. said Friday its treatment, solanezumab, failed to slow mental or cognitive decline in two late-stage studies. But combined data from both trials showed a statistically significant slowing of cognitive decline, as did a subgroup of patients with mild cases of the disease. Cognitive function involves memory.

Lilly said it will discuss the results with regulators and plan the next steps.

Current Alzheimer’s treatments only temporarily ease symptoms such as memory loss, confusion and agitation. They don’t slow, stop or reverse mental decline.

Drugmakers have tried and failed for years to develop successful treatments for the disease, and patients and doctors are anxious for any signs of promise. Analysts have said an approved treatment that slows the disease’s progression could be worth billions of dollars in sales.

Earlier this month, Pfizer Inc. and Johnson & Johnson said they will end development of an intravenous version of their potential Alzheimer’s treatment, bapineuzumab, after two late-stage studies showed it worked no better than a placebo in patients with mild-to-moderate cases.

Comments
(0)
Comments-icon Post a Comment
No Comments Yet
*We welcome your comments on the stories and issues of the day and seek to provide a forum for the community to voice opinions. All comments are subject to moderator approval before being made visible on the website but are not edited. The use of profanity, obscene and vulgar language, hate speech, and racial slurs is strictly prohibited. Advertisements, promotions, spam, and links to outside websites will also be rejected. Please read our terms of service for full guides